Blog

Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer

Pashtoon M. Kasi/hoosiercancer.org

Nov 21, 2024, 16:37

Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post on X:

“New Drug approval!

Precision Medicine.

HER2-targeted bispecific antibody.

Zanidatamab-hrii for HER2(IHC 3+) Biliary Tract Cancer (BTC).

Trials possible for ‘rare’ cancers like cholangiocarcinoma. More options for our patients.

Click here to read more.”

Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer

Dr. Pashtoon Kasi is the Medical Director of GI Medical Oncology at City of Hope, Orange County. Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Iowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of Iowa and Mayo Clinic. He also served as the Director of Colon Cancer Research and Director of Precision Medicine Research for Liquid Biopsies at Weill Cornell Medicine.His research primarily focuses on “liquid biopsies,” particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Dr. Kasi is also recognized as an author and editor of several significant books, including “Research: What, Why, and How: A Treatise from Researchers to Researchers” and “Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies.” His scholarly contributions extend to over 100 publications in esteemed peer-reviewed journals. He also received the Yvonne Award 2024 by OncoDaily in the “challenging the status quo” category.